Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC3R | P41968 | 4/20 | 0.40 |
| ▸ | MC4R | P32245 | 3/20 | 0.40 |
| ▸ | DPP4 | P27487 | 4/20 | 0.39 |
| ▸ | FAP | Q12884 | 2/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.39 |
| ▸ | TPH1 | P17752 | 2/20 | 0.36 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MC1R | Q01726 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6700410 | 0.92 | ITGA4 (0.40) | — | |
| SCHEMBL6698030 | 0.91 | MC4R (0.40) | MC3RMC4RDPP4FAPDPP8 | |
| SCHEMBL6383837 | 0.86 | ROCK2 (0.38) | DPP4DPP7 | |
| SCHEMBL6295858 | 0.78 | EPHX1 (0.33) | MC3RMC4RPOLBMC1R | |
| SCHEMBL6696901 | 0.78 | USP30 (0.42) | — | |
| SCHEMBL6294795 | 0.77 | CTSB (0.49) | — | |
| SCHEMBL6992575 | 0.76 | USP30 (0.48) | — | |
| SCHEMBL6703064 | 0.74 | HPGDS (0.47) | — | |
| SCHEMBL6300585 | 0.70 | CTSL (0.39) | — | |
| SCHEMBL6988909 | 0.69 | SLC6A3 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106805-A1 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LIMITED (GB) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106805-A1 | Inhibitors of cruzipain and other cysteine proteases | CTRL, CPN1, CPA1 | MC3R 3846/4885MC4R 4329/4885DPP4 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.